Efficacy of SNX-1012 in the Treatment of Oral Mucositis
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Oral mucositis (OM) is a common and debilitating toxicity induced by many chemotherapy (CT)
regimens and by radiation to the head and neck. The purpose of this study is to determine the
effectiveness of SNX-1012 in decreasing the duration of Grade 2, 3, or 4 oral mucositis (OM)
according to World Health Organization (WHO) criteria.